Actinium Pharmaceuticals, Inc. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDERS MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES. Market Information Our common stock is listed for quotation on the NYSE American under the symbol “ATNM”. Holders As of March 30, 2026, there were 31,175,949 shares of common stock issued and outstanding, which were held by approximately 100 holders of record. There are no shares of preferred stock outstanding. Dividends We have never declared or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. The decision to pay dividends is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, capital requirements, and other factors that our Board of Directors deems relevant. Securities Authorized for Issuance under Equity Compensation Plans We currently have one equity compensation plan. The Company’s 2019 Amended and Restated Stock Plan, (the “2019 Plan”) has an expiration date of October 18, 2029 and the number of shares of our common stock authorized under the plan for grant to employees, directors and consultants is 9,333,333 shares. The following table indicates shares of common stock authorized for issuance under our equity compensation plan as of December 31, 2025: Plan category Number of securities to be issued upon exercise of outstanding options and restricted stock units Weighted- average exercise price of outstanding options Number of securities remaining available for future issuance Equity compensation plans approved by security holders 398,898 $ 5.89 8,882,721 Equity compensation plans not approved by security holders - - - Total 398,898 $ 5.89 8,882,721 73 ITEM 6. RESERVED.